Harbin Pharmaceutical Group announced on October 11 that director and president Lu Chuanyou recently received a case filing notice and a detention notice from the relevant supervisory committee. The company said it has made proper arrangements for related work, the chairman, other directors and senior management are performing their duties normally, and the board of directors is operating normally. The announced matter will not have a significant impact on the company's production, operation and management. In the first half of 2026, Harbin Pharmaceutical Group achieved revenue of 8.296 billion yuan and net profit attributable to the parent of 410 million yuan.
Harbin Pharmaceutical Group Co LtdDirector and president Lu Chuanyou was detained by a supervisory committee, a legal/regulatory action against the company's leadership.
